Overview

Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis

Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label trial investigating the efficacy and safety of abatacept in ankylosing spondylitis. It is planned to treat 30 patients with ankylosing spondylitis from baseline up to week 30. Abatacept will be administered intravenously according to the prescription used in rheumatoid arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborator:
Bristol-Myers Squibb
Treatments:
Abatacept